张熠丹;马文斌;王任直;

• 1:中国医学科学院北京协和医学院临床医学系
• 2:中国医学科学院 北京协和医学院 北京协和医院神经外科

摘要(Abstract)：

<正>胶质细胞瘤是中枢神经系统发病率第一位的原发性肿瘤,其中世界卫生组织(World Health Organi-zation,WHO)分级Ⅲ、Ⅳ级被称为恶性胶质瘤,恶性胶质瘤的发病率约为5～8/10万,约占所有胶质细胞瘤的50%[1]。在替莫唑胺等新型化疗药和其他靶向药物出现之前,即使是最积极的手术、放化疗

关键词(KeyWords)： 恶性胶质瘤;胶质母细胞瘤;化疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张熠丹;马文斌;王任直;

Email:

DOI:

参考文献(References)：

• [1]Davis FG,McCarthy BJ.Current epidemiological trends and surveillance issues in brain tumors[J].Expert Rev Anticancer Ther,2001,1:395-401.
• [2]Avgeropoulos NG,Batchelor TT.New treatment strategies for malignant gliomas[J].Oncologist,1999,4:209-224.
• [3]Ushio Y,Hayakawa T,Hasegawa H,et al.Chemotherapy of malignant gliomas[J].Neurosurg Rev,1984,7:3-12.
• [4]Macdonald DR,Cascino TL,Schold SC,et al.Response criteria for phaseⅡstudies of supratentorial malignant glio-ma[J].J Clin Oncol,1990,8:1277-1280.
• [5]Levin VA,Crafts DC,Norman DM,et al.Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors[J].J Neurosurg,1977,47:329-335.
• [6]Kornblith PL,Walker M.Chemotherapy for malignant gliomas[J].J Neurosurg,1988,68:1-17.
• [7]Anderson B,Anderson B Jr.Necrotizing uveitis incident to perfusion of intractraial malignancies with nitrogen mustard or related compounds[J].Trans Am Ophthalmol Soc,1960,58:95-104.
• [8]Galanis E,Buckner JC,Burch PA,et al.PhaseⅡtrial of nitrogen mustard,vincristine,and procarbazine in patients with recurrent glioma:North Central Cancer Treatment Group results[J].J Clin Oncol,1998,16:2953-2958.
• [9]Walker MD,Alexander E Jr,Hunt WE,et al.Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas.A cooperative clinical trial[J].J Neurosurg,1978,49:333-343.
• [10]Chang CH,Horton J,Schoenfeld D,et al.Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas.A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study[J].Cancer,1983,52:997-1007.
• [11]Kaye AH,Laidlaw JD.Chemotherapy of gliomas[J].Curr Opin Neurol Neurosurg,1992,5:526-533.
• [12]Lassman LP,Pearce GW,Gang J.Sensitivity of intracranial gliomas to vincristine sulphate[J].Lancet,1965,1:296298.
• [13]Kaneko S,Abe H,Aida T,et al.Evaluation of radiation immunochemotherapy in the treatment of malignant glioma.Combined use of ACNU,VCR and PS-K[J].Hokkaido Igaku Zasshi,1983,58:622-630.
• [14]Hildebrand JG.Chemotherapy of malignant glioma.Results of studies of the EORTC group of brain tumors[J].Rev Neurol(Paris),1992,148:435-440.
• [15]Jeremic B,Jovanovic D,Djuric LJ,et al.Advantage of postradiotherapy chemotherapy with CCNU,procarbazine,and vincristine(mPCV)over chemotherapy with VM-26and CCNU for malignant gliomas[J].J Chemother,1992,4:123-126.
• [16]Ushio Y,Abe H,Suzuki J,Tanaka R,et al.Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas-a cooperative clinical trial[J].No To Shinkei,1985,37:999-1006.
• [17]Kitahara M,Katakura R,Mori T,et al.Combined effect ofACNU and5-fluorouracil on spheroids of rat glioma cells[J].Neurol Med Chir(Tokyo),1984,24:747-757.
• [18]Shapiro WR,Green SB,Burger PC,et al.A randomized comparison of intra-arterial versus intravenous BCNU,with or without intravenous5-fluorouracil,for newly diagnosed patients with malignant glioma[J].J Neurosurg,1992,76:772-781.
• [19]Menei P,Boisdron-Celle M,Croue A,et al.Effect of stereotactic implantation of biodegradable5-fluorouracil-loaded microspheres in healthy and C6glioma-bearing rats[J].Neurosurgery,1996,39:117-123;discussion23-24.
• [20]Stewart DJ,Richard MT,Benoit B,et al.Cisplatin plus cytosine arabinoside in adults with malignant gliomas[J].J Neurooncol,1984,2:29-34.
• [21]Luyendijk W,van Beusekom GT.Chemotherapy of cerebral gliomas with intra-carotid methotrexate-infusion[J].Acta Neurochir(Wien),1966,15:234-248.
• [22]Dhanikula RS,Argaw A,Bouchard JF,et al.Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas:enhanced efficacy and intratumoral transport capability[J].Mol Pharm,2008,5:105-116.
• [23]Hayakawa T,Ushio Y,Mogami H,et al.The uptake,distribution and anti-tumor activity of bleomycin in gliomas in the mouse[J].Eur J Cancer,1974,10:137-142.
• [24]Zhao KM,Chen JM,Zuo HZ,et al.Modulation of O6-methylguanine-DNA methyltransferase-mediated nimustine resistance in recurrent malignant gliomas by streptozotocin-a preliminary report[J].Anticancer Res,1995,15:645-648.
• [25]Yoshida D.Clinical research of the treatment of malignant gliomas by local administration of adriamycin.A statistical study of118cases[J].Nippon Ika Daigaku Zasshi,1988,55:544-554.
• [26]Pouillart P,Mathe G,Thy TH,et al.Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin,VM26,and CCNU.Results of a phaseⅡtrail[J].Cancer,1976,38:1909-1916.
• [27]Glioma meta-Analysis Frialists(GMT)Group.Chemotherapy for high-grade glioma[J].Cochrane Database Syst Rev,2002:CD003913.
• [28]Louis DN,Ohgaki H,Wiestler OD,et al.The2007WHO classification of tumours of the central nervous system[J].Acta Neuropathol,2007,114:97-109.
• [29]Stevens MF,Hickman JA,Stone R,et al.Antitumor imidazotetrazines.1.Synthesis and chemistry of8-carbamoyl-3(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one,a novel broad-spectrum antitumor agent[J].JMed Chem,1984,27:196-201.
• [30]O'Reilly SM,Newlands ES,Glaser MG,et al.Temozolomide:a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours[J].Eur J Cancer,1993,29A:940-942.
• [31]Stupp R,Mason WP,van den Bent MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].N Engl J Med,2005,352:987-996.
• [32]Hegi ME,Diserens AC,Gorlia T,et al.MGMT gene silencing and benefit from temozolomide in glioblastoma[J].N Engl J Med,2005,352:997-1003.
• [33]Fukushima T,Takeshima H,Kataoka H.Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT[J].Anticancer Res,2009,29:4845-4854.
• [34]Vredenburgh JJ,Desjardins A,Herndon JE,et al.Bevacizumab plus irinotecan in recurrent glioblastoma multiforme[J].J Clin Oncol,2007,25:4722-4729.
• [35]Vredenburgh JJ,Desjardins A,Herndon JE,et al.PhaseⅡtrial of bevacizumab and irinotecan in recurrent malignant glioma[J].Clin Cancer Res,2007,13:1253-1259.
• [36]Tong RT,Boucher Y,Kozin SV,et al.Vascular normalization by vascular endothelial growth factor receptor2blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[J].Cancer Res,2004,64:3731-3736.
• [37]Bao S,Wu Q,Sathornsumetee S,et al.Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor[J].Cancer Res,2006,66:78437848.
• [38]Friedman HS,Petros WP,Friedman AH,et al.Irinotecan therapy in adults with recurrent or progressive malignant glioma[J].J Clin Oncol,1999,17:1516-1525.
• [39]Zuniga RM,Torcuator R,Jain R,et al.Efficacy,safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan[J].J Neurooncol,2009,91:329-336.
• [40]Franceschi E,Cavallo G,Scopece L,et al.PhaseⅡtrial of carboplatin and etoposide for patients with recurrent highgrade glioma[J].Br J Cancer,2004,91:1038-1044.
• [41]Sheleg SV,Korotkevich EA,Zhavrid EA,et al.Local chemotherapy with cisplatin-depot for glioblastoma multiforme[J].J Neurooncol,2002,60:53-59.
• [42]Verhaak RGW,Hoadley KA,Purdom E.An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA,IDH1,EGFR and NF1[J].Cancer Cell,2010,17:98-101.
• [43]Van MEG,Hadjipanayis CG,Norden AD.Exciting new advances in neuro-oncology:the avenue to a cure for malignant glioma[J].CA Cancer J Clin,2010,60:166-193.
• [44]Schor NF.Pharmacotherapy for adults with tumors of the central nervous system[J].Pharmacol Ther,2009,121:253-264.
• [45]Tews DS,Nissen A,Kulgen C,et al.Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors[J].J Neurooncol,2000,50:227237.
• [46]Haga S,Hinoshita E,Ikezaki K,et al.Involvement of the multidrug resistance protein3in drug sensitivity and its expression in human glioma[J].Jpn J Cancer Res,2001,92:211-219.
• [47]Kappadakunnel M,Eskin A,Dong J,et al.Stem cell associated gene expression in glioblastoma multiforme:relationship to survival and the subventricular zone[J].J Neurooncol,2010,96:359-367.
• [48]Eramo A,Ricci-Vitiani L,Zeuner A,et al.Chemotherapy resistance of glioblastoma stem cells[J].Cell Death Differ,2006,13:1238-1241.
• [49]Hussain SF,Heimberger AB.Immunotherapy for human glioma:innovative approaches and recent results[J].Expert Rev Anticancer Ther,2005,5:777-790.